Arylated 5-hydroxy-pyrrol-2-ones were prepared in 2 synthetic steps from muco-chloric acid and optimised as CCK 2 selective ligands using radiolabelled binding assays. CCK antagonism was confirmed for the ligands in isolated tissue preparations. DSS (dextran sulfate sodium) induced inflammation was analysed for derivative 7 and PNB-001 with L-365,260 as standard. The IC 50 of PNB-001 was determined as 10 nM. Subsequent in vivo evaluation confirmed anti-inflammatory activity with respect to IBD assays. The best molecule, PNB-001, showed analgesic activity in the formalin test and in the hotplate assay the analgesic effect of 1.5 mg/kg PNB-001 was equivalent to 40 mg/kg tramadol. The CCK 2 selective antagonist PNB-001 protected rats against indomethacin induced ulceration at similar doses. The GI protection activity was found more potent than the 10 mg/kg dose of prednisolone, which served as standard.
Introduction
Inflammatory bowel syndrome (IBS) is a complex symptom of unknown ethology, characterized by abdominal pain or discomfort associated with disturbed defecation and often bloating. Inflammatory bowel disease (IBD) encompasses at least two forms of intestinal inflammation being expressed as ulcerative colitis and Crohn's disease. Although many other inflammatory disorders affect the gastrointestinal tract, most can be distinguished by a specific underlying process from IBD. Stress may exacerbate IBS symptoms and the CCK 2 receptor is known to mediate anxiety 1 and panic attacks. Though several drugs such as anti-cholinergic-, antispasmodic-agents and tricyclic anti-depressants are of limited use for IBS and steroids for IBD, inflammatory bowel disease is still classified as unmet medical need and hundreds of studies are ongoing worldwide.
Aim of the drug discovery programme was to target the underlying mechanism of the disease, thus targeting Cholecystokinin (CCK) pathways. CCK, a peptide hormone, which is extensively found in the gastrointestinal tract (GIT) is widely distributed through the nervous system 2 . Cholecystokinin acts as a neuromodulator / gut hormone and CCK-ligands, agonists as well as antagonists 3 , have been extensively investigated as potential drug targets 4 . CCKantagonists were studied as growth inhibitors in certain forms of cancer 5 , as anxiolytics 6 , in the treatment of schizophrenia 7 , satiety 8 and as anti-panic agents 9 . An agonist, the shortened CCK tetrapeptide, was found to induce panic in patients 10 .
Despite the progress of several CCK receptor antagonists 11 to different phases of clinical trials, only proglumide was marketed as Milid for the treatment of gastric ulcer. Merck's standard CCK 2 antagonist 12 is outlined in Figure 1 . Z-360 is the most recent derivative derived from this original lead structure, in which the N was moved to the 5-position. The N-1 was alkylated, the 5 phenyl group was replaced by a cyclohexyl group and the water solubility was enhanced by converting the Me group on the side chain into a carboxylic acid. All structural optimisations did not address the main underlying problem with respect to poor pharmacokinetic properties, such as a low solubility and very low membrane penetration resulting from the large polar surface area of the molecule.
PNB Vesper Life Science systematically investigated the hydroxylpyrrolone scaffold and the isobutyl derivative 13 served as lead structure on this programme towards novel anti-inflammatory analgesics targeting the underlying mechanism of inflammatory ulceration.
A full biological evaluation of lactame 14, now PNB-001, will be reported here, in this publication from a CCK-5 pentagastrin antagonism to initial anti-inflammatory analgesic activity.
Results and discussions

Synthesis
Mucochloric acid was reacted in presence of a Lewis acid via S E reactions into a series of arylated dichlorinated furanones. In addition to halogenated X=Cl, F 5-arylated 2(5H)-furanones containing further donor substituents were prepared. The chemical yields were generally lower and binding affinity was also decreased in the resulting final molecules. Arylated 2(5H)-furanones, containing nitro-groups or trifluoro-methyl groups could not be prepared.
Subsequent reaction of the 5-arylated 3,4-dichloro-2(5H)-furanones with amines, in particular with aryl alkyl amines, furnished 15 arylated N-alkylated hydroxyl-pyrrolones and the 2 nd step of the synthetic sequence is outlined in Scheme 1. The 5-arylated 2(5H)-furanones reacted selectively in the ester position and no reaction in the 4-position was observed. Previously the substitution in the 4-position was described for pseudoesters 14 , and here a ring -opening ring -closure mechanism for the formation of hydroxyl-pyrrolones is proposed in scheme 2.
The first step in the reaction sequence of the dichlorinated 2(5H)-furanone is the ring opening and amide formation from the corresponding lactone. The keto form of the acyclic amide was then in situ converted into a lactame under the elimination of hydrogen chloride.
Analysis by chiral HPLC showed a 50:50 racemic mixture of the novel template in solution in methanol.
Scheme 2.
Chemical mechanism for the formation of 5-hydroxy-5-aryl-pyrrol-2-ones with amines.
SAR optimisation
Initially SAR were fully explored and optimised for the CCK 2 /gastrin receptor, using a radiolabelled binding assay with iodinated CCK 8 . The results, expressed in IC 50 , are outlined in table 1.
Lorglumide served as CCK 1 standard and L-365,260 was used as CCK 2 standard. For a better comparison the initial starting point, the CCK 1 antagonist PNB-028, is also included in Table 1 .
Cyclic substituents on the N-position, such as cyclopropyl-, cyclopentyl-and cyclohexyl provided activity in the micromolar range (Lactame 1-5). Anilines were inactive and the introduction of the benzyl group furnished a dual ligand in nanomolar range (lactame 7). Halogen atoms on the 5 phenyl group marginally enhanced the binding affinity and the best derivative was the fluorinated N-benzyl lactame 9.
Donor substituents on the 5-phenyl group, such as para-methoxy and methyl groups resulted in ligands with manifold lower activity (lactame 10, 11). The introduction of a chiral amine, such as methyl benzyl amine provided diastereoisomers (12, 13), which were separated by column chromatography, but both isomers occurred a lower affinity than the parent benzyl derivative 7. Further optimisation on the N-benzyl group was performed, but the introduction of a para F-and methoxy-group, using p-fluorobenzyl amine and p-methoxy benzylamine, did not enhance the binding affinity for the CCK receptor.
The introduction of a spacer, a single CH 2 group, resulted in a phenyl-ethyl derivative 14, which represented a highly CCK 2 selective ligand. Lactame 14 is 450 times selective for the CCK 2 / gastrin receptor. Halogenation, the introduction of a para-chlorine atom on the phenyl-position, lactame 15, did not enhance binding affinity any further; possibly due to drug receptor interaction of the phenyl group with a lipophilic cavity within the CCK receptor. 
Molecular modelling -Ligand docking
The docking of the phenylethyl pyrrolone 14 into the CCK 2 receptor is outlined in figure 2 for one final pose of minimal energy and some key drug receptor interactions are highlighted.
The 2-carbonyl group of the central pyrrolone template interacts via hydrogen binding with the N group of Trp-114. The phenyl group of the N-phenylethyl-side chain binds towards the aromatic indole system of Trp-114 and electron withdrawing groups should enhance these aromatic interactions. The lipophilic pocket in the CCK 2 receptor comprising of Ile-184 and Leu-133, allows principally a wide range of substituents, but only phenyl and not cyclo-hexyl can be realised synthetically. The 5-phenyl group of the pyrrolone template binds via Ile-184 and Leu-133, based on van der Waals interactions and not aromatic interactions. Therefore, the introduction of electron withdrawing groups on the 5-phenyl group, such as a chlorine atom, do not enhance binding affinity and optimisation on this side is overall with limited effect. Interestingly, the metabolism of the 5-phenyl derivative 14, may result in a phydroxy-phenyl metabolite, which may interact additionally with His-122 via a strong hydrogen bond and the role of metabolites is currently under investigation. The molecular structure of lactame 14, (Table 1) which is now PNB-001 was designed from an iso-propyl lead structure via the benzyl derivative 7 (Figure 3 ). PNB-001 contains the N-phenyl-ethyl substituent, which is required for high CCK 2 / gastrin selectivity 15 . The mixed dual acting N-benzylated pyrrolone 7 (Table 1) is showing the expected pharmacological profile of a mixed CCK COMMUNICATION Journal Name antagonist 16 and its role in brain cancer is currently being elucidated.
The phenyl ethyl derivative PNB-001 completed preclinical development as anti-inflammatory analgesic and progressed into Phase 1 clinical trials for the treatment of IBD.
Isolated tissue preparations
CCK antagonism
The CCK 2 selective ligand PNB-001, occurred a potent binding affinity and the CCK-antagonism was studied 17 using pentagastrin, CCK-5 induced contractions of the rat duodenum.
Initially CCK 4 was used 18 , but CCK 4 has a low solubility and low potency in the micro-molar range. The best CCK 2 selective agonist is CCK-5 and this was used to analyse the agonist or antagonist properties of the ligand. As the clinical trial outcome of selective CCK/gastrin antagonists was found questionable in the treatment of anxiety and depression 20 , the aim of the programme was, to focus on selectively designing CCK 2 antagonists for the gastrointestinal system and to focus on inflammation thereof.
Inflammatory bowel disease, IBD, is classified an unmet medicinal need by the FDA and allows fast track approval. The indomethacin induced ulceration is a standard in vivo assay for IBD 21 .
In vitro inflammation
In vitro, spontaneous contractions correlate with inflammation and anti-inflammatory steroids such as dexamethasone reduced spontaneous contractions of the duodenum 22 .
DSS, dextran sulfonic acid sodium, is a standard agent to induce inflammation for IBD in vivo and in vitro the effect is slower and milder than for Trinitro-benzene sulfonic acid, TNBSA 23 .
DSS was used here in vitro using isolated organ preparations and preparations of the duodenum worked best in this assay 24 .
L-365,260 was applied as CCK 2 standard and the mixed CCK antagonist HPhBz, lactame 7, together with the highly CCK 2 selective antagonist PNB-001 were all tested under the same conditions. The concentration response curves, showing how these agents inhibit contractions a very low concentrations, are outlined in Figure 5 . An IC 50 of 1 nM was determined for CCK 2 antagonist PNB-001. The Merck CCK 2 standard occurred a ten times lower IC 50 and the benzylated derivative HPhBz, lactame 7, had the lowest antiinflammatory effect. Considering the chemical similarity between the lactame 7 and PNB-001, the addition of an extra CH 2 group resulted in a remarkable effect. The CCK 1 antagonism may oppose the anti-inflammatory effect, but the possible mechanistic pathway is outside the scope of this publication.
Based on the in vitro results with respect to anti-inflammatory activity, PNB-001 was selected for further in vivo assays. This programme was concerned with inflammation of the GI tract and the indomethacin induced ulceration is the best model for IBD, inflammatory bowel disease and ulcerative colitis, which is associated with the release of gastric acid. Here, the antiinflammatory action of the molecule, supported by anti-gastric activity, was supposed to create a synergistic therapeutic effect.
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In vivo evaluation
Inflammatory/ulceration protection Gastrin triggers the release of gastric acid in the stomach and the content of the GI system moves from the duodenum, jejunum via ileum to the colon. The inflammation was assessed in this order by organ weight and inflammation scores. The measurement of weight as inflammation parameter is reliable and the induction of inflammation / ulceration resulted in an increased organ weight. Figure 6 . Indomethacin induced ulceration. Weights of the GI tract treated by PNB-001.
Weights of different parts of GI tract
Indomethacin increased weight in all observed organ parts and this increase of weight was reduced dose dependently by PNB-001 for the duodenum, jejunum, and ileum. The effect of protection is observed for all parts of the GI system and PNB-001 performed better than the steroid standard prednisolone.
The second accessed parameter was scores of inflammation and the results are outlined in Figure 7 . Treatment is presented for each individual organ and scores of inflammation were determined. Most interestingly the gaps in the treatment groups with zero inflammation are present in the duodenum for both the 5 and the 20 mg /kg dose of PNB-001 via oral administration. Indomethacin induced an inflammation score of 5 in the duodenum, which was fully protected by both doses of the CCK B antagonist and reduced to 2 by prednisolone at 10 mg/kg.
In figure 8 selected photos of the gastrointestinal system with ulceration are depicted. In the duodenum the perforation is clearly visible and this is fully prevented by a low 5 mg /kg dose of PNB-001. A similar effect is seen for the jejunum on indomethacin induced ulcers and this damage of the GI system was prevented by PNB-001. Analgesic evaluation CCK antagonists potentiate the analgesia of opiates and usually, except for proglumide, have no analgesic effect on their own 25 . For Z-360 an interesting weak analgesic effect in the formalin test was observed 26 .
Thus, a first evaluation of the analgesic properties of PNB-001 was performed using the formalin test. Opiates, such as morphine, reduce the response in form of licks and bites to formalin in the first phase of the assay. Anti-inflammatory agents are active in this assay in the second phase.
PNB-001 showed only at the 1.5 mg/kg dose some opiate like effects (phase 1) and displayed at this dose also the best antiinflammatory effect (phase 2). The 5 mg dose by IP administration is equivalent to the 20 mg/kg dose by oral administration, but had a lower analgesic effect than the 1.5mg/kg dose. However, the activity in the second phase of the formalin test, reconfirmed the anti-inflammatory activity found in vitro and in vivo.
In order to evaluate the pain managing properties of the new agent, the partial opiate agonist tramadol was included in a last study, in which the hot plate assay was used to evaluate analgesic activity. The analgesic efficacy of 0.5 mg/kg PNB-001 by IP administration as a single agent was found equivalent to 40 mg/kg tramadol (SC administration). Interestingly, there is no significant potentiation of tramadol analgesia with PNB-001. The selective CCK 2 / gastrin antagonist, worked here in this assay as analgesic on its own. This analgesic activity may be found useful in the treatment of IBD/IBS pain, additionally.
Hot Plate Test
Conclusions
This novel template, which originally occurred CCK 1 activity 27 was optimised as CCK 2 /gastrin selective antagonist.
The target molecule was synthesised in only 2 steps from readily available starting materials and will potentially deliver affordable therapeutic agents.
By designing a potent CCK 2 /gastrin antagonist for inflammatorydiseases and not CNS disorders, a first in class CCK 2 antagonist with analgesic anti-inflammatory activity was developed under the consideration of membrane penetration, half-life and bioavailability.
By focussing on unmet medical needs such as inflammatory bowel disease, IND was granted in India and the FDA approval is expected for late 2019.
The mild analgesic effect of PNB-001 may offer an alternative drug treatment to Tramadol, which is closing the gap of pain management between NSAIDs and opiates.
